The Psychedelic Therapy Workbook: Harm Reduction Techniques for Integrating Psychedelics in Therapy and Personal Growth

Unlock the healing and transformative benefits of psychedelic therapy with this powerful, practical, evidence-based guide.

If you’ve sought conventional treatment for depression, anxiety, substance-use disorder, or post-traumatic stress disorder (PTSD) and have been disappointed by a lack of positive results, know that you’re not alone. The good news is that there is hope. More and more, research shows the tremendous benefit of psychedelic drugs like psilocybin, MDMA, LSD, and ketamine for people suffering from difficult-to-treat mental health issues. But how do you integrate them into your life effectively?

In The Psychedelic Therapy Workbook, psychologists Elizabeth Nielson and Ingmar Gorman present a pioneering approach to maximizing the therapeutic potential of psychedelics. Drawing on their extensive experience and research, the authors introduce their psychedelic harm reduction and integration (PHRI) method, offering a comprehensive framework for integrating the lessons you’ve learned from psychedelic experiences into your daily life.

With this step-by-step guide, you will:

• Learn how to choose the right setting and set intentions for a positive experience
• Explore evidence-based practices to ensure healing and growth
• Empower yourself to navigate the psychedelic landscape with confidence and mindfulness

Whether you’re embarking on a therapeutic journey with a guide, in a group, or with a therapist, this workbook provides the tools you need to explore the benefits of psychedelics for profound transformation, healing, and self-discovery.

Elizabeth Nielson, PhD, is a psychologist, and cofounder of Fluence. She served as site coprincipal investigator of an FDA-approved Phase 3 clinical trial of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), and worked  on developing psychedelic therapies through conduct of additional FDA-approved trials of psychedelics for substance use problems and mood disorders. Nielson has published research on psychedelic therapies, psychedelic therapist training, and ethical considerations for the future of the field. Nielson has worked as an educator for clinicians for over a decade, and continues to create training programs to ensure the highest-quality care for psychedelic users.

Ingmar Gorman, PhD, is a psychologist, educator, and cofounder of Fluence. As site coprincipal investigator on FDA Phase 2 and Phase 3 clinical trials of MDMA-assisted therapy for PTSD, Gorman has been at the forefront of groundbreaking research in psychedelic-assisted psychotherapy. He has authored numerous publications on psychedelics, harm reduction, and integration therapy. Through his private practice and contributions to the field, Gorman continues to shape the future of mental health care.